American College of Emergency Physicians Quality Measures. Status: Draft For Public Comment Do Not Cite. Available: September 16, 2014

Size: px
Start display at page:

Download "American College of Emergency Physicians Quality Measures. Status: Draft For Public Comment Do Not Cite. Available: September 16, 2014"

Transcription

1 American College of Emergency Physicians Quality Measures Status: Draft For Public Comment Do Not Cite Available: September 16, 2014 Obsolete After: October 17, 2014

2 Page 2 of 23 Table of Contents Table of Contents Page Disclaimer 3 Quality Measures Technical Expert Panel Objectives & Acknowledgments 4 Quality Measures Technical Expert Panel Roster 5 Measure #1: Emergency Department Utilization of CT for Minor Blunt Head Trauma for 6 Patients Aged 18 Years and Older Measure #2: Emergency Department Utilization of CT for Minor Blunt Head Trauma for 10 Patients Aged 2 Through 17 Years Measure #3: Coagulation Studies in Adult Patients Presenting with Chest Pain with No 15 Coagulopathy or Bleeding Measure #4: Appropriate Emergency Department Utilization of CT for Pulmonary 18 Embolism References for All Measures 22

3 Page 3 of 23 Disclaimer Physician Performance Measures (Measures) and related data specifications developed by the American College of Emergency Physicians (ACEP) are intended to facilitate quality improvement activities by physicians. These measures are intended to assist physicians in enhancing quality of care. These Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. ACEP encourages testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by ACEP. The measures may not be altered without prior written approval from ACEP. The measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by health care providers in connection with their practices). Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measures into a product or service that is sold, licensed, or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and ACEP. Neither ACEP nor its members shall be responsible for any use of the measures. THESE MEASURES AND SPECIFICATIONS ARE PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND American College of Emergency Physicians. All rights reserved. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary coding sets should obtain all necessary licenses from the owners of these code sets. ACEP and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT ) or other coding contained in the specifications. ICD-10 copyright 2012 International Health Terminology Standards Development Organization CPT is a registered trademark of the American Medical Association and is copyright CPT codes contained in the Measure specifications are copyright American Medical Association.

4 Page 4 of 23 Quality Measures Technical Expert Panel Objectives The ACEP Board of Directors approved the development of quality measures to protect and enhance emergency care in February 2013 with the following objectives: To define the value of emergency care and develop a set of performance measures that will meet the criteria for the CMS value-based payment modifier (VBPM), which must apply to all physicians by legislative mandate by 2017 based on the 2015 quality reporting period. To develop new performance measures for inclusion in the Physician Quality Reporting System (PQRS) and other programs to enhance and protect emergency care. To continue the ongoing cyclical work of, testing, updating and maintaining ACEP s current performance measures for CMS reporting programs. To identify areas for internal quality improvement through MOC Part IV, OPPE, and other QI and data collection activities for important topics. Acknowledgement This measure set was made possible in part by the generous support of the American Board of Emergency Medicine(ABEM) and the Emergency Medicine Action Fund (EMAF). Quality Measures The American College of Emergency Physicians (ACEP) convened a Quality Measures Technical Expert Panel (TEP) to assess opportunities for the development of evidence-based performance measures. The ACEP QMs TEP proposes this set of measures to address gaps in care around emergency medicine with a focus on appropriateness and with the aim of optimizing clinical outcomes.

5 Page 5 of 23 Technical Expert Panel Roster Co-Chairs Jeremiah D. Schuur, MD, MHS, FACEP Stephen V. Cantrill, MD, FACEP American College of Emergency Physicians James Augustine, MD, FACEP Robert I. Broida, MD, FACEP Kathleen Brown, MD, FACEP Vidor E. Friedman, MD, FACEP Michael Granovsky, MD, FACEP Joseph A. Halpern, MD, FACEP Timothy C. Hsu, MD, FACEP Richard Newell, MD, MPH, FACEP Michael P. Phelan, MD FACEP William E Reisinger, III, DO, FACEP Paul Sierzenski, MD, RDMS, FACEP Joshua Howland Tamayo-Sarver, MD, FACEP Arjun Venkatesh, MD, MBA L. Kendall Webb, MD AIM Specialty Health Susan Nedza, MD, MBA, FACEP American Academy of Family Physicians Andrew Eisenberg, MD, MHA American Academy of Neurological Surgeons David Okonkwo, MD, PhD American Academy of Neurology Steven Mandel, MD, FAAN Becky Schierman, MPH (Staff) American Academy of Pediatrics Evaline Alessandrini, MD, FAAP Council of Medical Specialty Societies Sharon Hibay, RN, DNP American Board of Emergency Medicine Michael L Carius, MD, FACEP Terry Kowalenko, MD, FACEP Robert Philip Wahl, MD, FACEP American College of Radiology American College of Neuroradiology Ari Blitz, MD Judy Burleson, MHSA (Staff) American Society of Hematology Neil Zakai, MD, MSc Robert Plovnick, MD (Staff) Emergency Medicine Action Fund Wesley Fields, MD, FACEP The Joint Commission Dan Castillo, MD, MBA, FACEP Quality Measures Methodology Sharon Hibay, RN, DNP Society of Critical Care Medicine Julie Mayglothling, MD, FACEP, FCCM AMA-PCPI Consultants Kendra Hanley, MS Jennifer Heffernan, MPH Meredith Jones, MPH Kimberly Smuk, RHIA Samantha Tierney, MPH ACEP Staff Dainsworth Chambers Diana Crowley, MPH Stacie Schilling Jones, MPH David McKenzie

6 Page 6 of 23 For Public Commnet: ACEP Draft Quality Measures Measure #1: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older For this measure higher score indicates higher quality Measure Description Percentage of emergency department visits for patients aged 18 years and older who presented within 24 hours of a minor blunt head trauma with a Glasgow Coma Scale (GCS) score of 15 and who had a head CT for trauma ordered by an emergency care provider who have an indication for a head CT Measure Components Numerator Statement emergency department visits for patients who have an indication for a head CT Indications for a head CT in patients presenting to the emergency department for minor blunt head trauma: Patients with any one of the following: Severe headache Vomiting Age 65 years and older Physical signs of a basilar skull fracture (signs include haemotympanum, panda eyes, cerebrospinal fluid leakage from the ear or nose, Battle s sign) Focal neurological deficit Coagulopathy Thrombocytopenia Currently taking any of the following anticoagulant medications: apixaban, argatroban, bivalirudin, dabigatran, dalteparin, desirudin, enoxaparinm fondaparinux, heparin, lepirudin, low molecular weight heparin, rivaroxaban, tinzaparin, warfarin Dangerous Mechanism (ie, ejection from a motor vehicle, a pedestrian struck, and a fall from a height of more than 3 feet or 5 stairs) OR Patients with either loss of consciousness OR posttraumatic amnesia AND any one of the following: Headache Age 60 years and older, and less than 65 years Drug/alcohol intoxication Short-term memory deficits Evidence of trauma above the clavicles (physical location, any trauma to the head or neck [ie, laceration, abrasion, bruising, ecchymosis, hematoma, swelling, fracture]) Posttraumatic seizure

7 Page 7 of 23 Statement All emergency department visits for patients aged 18 years and older who presented within 24 hours of a minor blunt head trauma with a Glasgow Coma Scale (GCS) score of 15 and who had a head CT for trauma ordered by an emergency care provider Definition: Presented within 24 hours - The 24 hour timeframe is based on the time of injury reported by the patient or caregiver or guardian. Exclusions Exceptions Rationale for the Measure note: Minor blunt head trauma includes only non-penetrating injuries. Patients with any of the following: Ventricular shunt Brain tumor Multisystem trauma Pregnancy Currently taking any of the following antiplatelet medications: ASA/dipyridamole clopidogrel prasugrel ticlopidine None This measure is needed to close the gap in provider performance as patients with mild closed head injuries without guideline indications for CT or MRI imaging are receiving such studies. The results of this are increased healthcare expenditures, unnecessary patient radiation exposure, and possibly prolonged evaluation times. This measure is an appropriateness measure, and as such is one for which a higher score indicates higher quality. The technical expert panel (TEP) considered an alternate measure construction, such that this measure would more closely match the pediatric measure; however, the feasibility issues posed by the alternate construction resulted in the construction as seen here. Supporting Guideline & Other Evidence The following evidence statements are quoted verbatim from the referenced clinical guidelines and other references: Level A recommendations. A noncontrast head CT is indicated in head trauma patients with loss of consciousness or posttraumatic amnesia only if one or more of the following is present: headache, vomiting, age greater than 60 years, drug or alcohol intoxication, deficits in short-term memory, physical evidence of trauma above the clavicle, posttraumatic seizure, GCS score less than 15, focal neurologic deficit, or coagulopathy (ACEP, 2008).i Level B recommendations. A noncontrast head CT should be considered in head trauma patients with no loss of consciousness or posttraumatic amnesia if there is a focal neurologic deficit, vomiting, severe headache, age 65 years or greater, physical

8 Page 8 of 23 Measure Importance signs of a basilar skull fracture, GCS score less than 15, coagulopathy, or a dangerous mechanism of injury.* *Dangerous mechanism of injury includes ejection from a motor vehicle, a pedestrian struck, and a fall from a height of more than 3 feet or 5 stairs (ACEP, 2008).ii Relationship to desired outcome Opportunity for Improvement Exception Justification Though it is difficult to directly attribute the effects of smaller dosages of radiation, such as that received through computed tomography (CT), the dosage of radiation from CTs has increased in recent years, in part due to the increased speed of image acquisition. Additionally, there is evidence to suggest that the radiation doses from CTs are higher and more variable than generally quoted. iii Further, as radiation doses associated with commonly used CT examinations resemble doses received by individuals in whom an increased risk of cancer was documented, iv the use of some CT scans is associated with a nonnegligible lifetime attributable risk of cancer. v vi As over 1.3 million individuals are treated and released from the ED for mild traumatic brain injury annually vii, it is critical that CT scans only be utilized when clinically appropriate. Through measurement of the share of CT scans that are performed inappropriately, a focus can be brought to quality improvement and increased application of clinical decision tools around this topic. About 2.5 million traumatic brain injuries occur each year, where 75% of these are considered mild. viii There is data to suggest that 70% of head injury patients receive a head CT ix, and it is estimated that 10-35% of head CTs obtained in head injury patients do not follow recognized guidelines. x Some estimate that as many as 55, ,000 CT scans are possibly avoidable annually. xi The ACEP Measure Work Group agreed to include appropriate medical reasons as an exception so that clinicians can exclude patients for whom CT imaging may be justified. Harmonization with Existing Measures Measure Designation Measure purpose (check all that apply) Type of measure National Quality Strategy Priority/CMS Measure Domain (check all that apply) Staff has considered harmonization with NQF 0668 Appropriate Head CT Imaging in Adults with Mild Traumatic Brain Injury. Quality improvement Accountability MOC Process Outcome Structure Clinical Process-Effectiveness Patient Safety Patient Experience Care Coordination Efficiency: Overuse

9 Page 9 of 23 Level of Measurement (check all that apply) Care setting (check all that apply) Data source (check all that apply) Efficiency: Cost Population & Community Health Individual clinicians Clinician groups Hospital Outpatient/ED Emergency Departments Urgent Care Harmonize with other care settings o Physician Office Based Measures o Hospital Level Measure Electronic health record (EHR) data Administrative Data/Claims (inpatient, outpatient or multiple-source claims) Paper medical record/chart abstracted Registry

10 Page 10 of 23 Measure #2: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years For this measure lower score indicates higher quality Measure Description Percentage of emergency department visits for patients aged 2 through 17 years presented within 24 hours of a minor blunt head trauma with a Glasgow Coma Scale (GCS) score of 15 and who had a head CT for trauma ordered by an emergency care provider and are classified as low risk according to the PECARN prediction rules for traumatic brain injury Measure Components Numerator Statement emergency department visits for patients classified as low risk according to the PECARN prediction rules for traumatic brain injury Definition: Low Risk for Traumatic Brain Injury according to PECARN prediction rules Patients can be classified as low risk if all of the following are met: No signs of altered mental status (eg, agitation, somnolence, repetitive questioning, slow response to verbal communication) No signs of basilar skull fracture (signs include haemotympanum, panda eyes, cerebrospinal fluid leakage from the ear or nose, Battle s sign) No loss of consciousness No vomiting No severe mechanism of injury (ie, motor vehicle crash with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorized vehicle; falls of more than 3 feet; or head struck by a highimpact object) No severe headache Statement All emergency department visits for patients aged 2 through 17 years who presented within 24 hours of a minor blunt head trauma with a Glasgow Coma Scale (GCS) score of 15 and who had a head CT for trauma ordered by an emergency care provider Definition: Presented within 24 hours - The 24 hour timeframe is based on the time of injury reported by the patient or guardian. Exclusions note: Minor blunt head trauma includes only non-penetrating injuries. Patients with any of the following: Ventricular shunt Brain tumor Coagulopathy Thrombocytopenia

11 Page 11 of 23 Exceptions Rationale for the Measure None This measure is needed to close the gap in provider performance as patients with mild closed head injuries without guideline indications for CT or MRI imaging are receiving such studies. The results of this are increased healthcare expenditures, unnecessary patient radiation exposure, and possibly prolonged evaluation times.. This measure is an overuse measure its intention is to capture those instances in which a pediatric patient is characterized as low risk yet still receives a CT. As such, the measure is scored such that a lower score indicates higher quality. The measure is constructed in this manner due to the available evidence; the PECARN clinical policy defines the low-risk population, but though medium and high risk populations are less well-defined. The measure then uses the definable population as its numerator, necessitating an overuse construction. Supporting Guideline & Other Evidence The following evidence statements are quoted verbatim from the referenced clinical guidelines and other references: Pediatric Emergency Care Applied Research Network (PECARN): Suggested CT algorithm for children younger than 2 years (A) and for those aged 2 years and older (B) with GCS scores of after head trauma:

12 Page 12 of 23 NICE: Head Injury Triage, assessment, investigation and early management of head injury in children and adultsxii For children who have sustained a head injury and have any of the following risk factors, perform a CT head scan within 1 hour of the risk factor being identified: Suspicion of non-accidental injury Post-traumatic seizure but no history of epilepsy. On initial emergency department assessment, GCS less than 14. At 2 hours after the injury, GCS less than 15. Suspected open or depressed skull fracture or tense fontanelle. Any sign of basal skull fracture (haemotympanum, 'panda' eyes, cerebrospinal fluid leakage from the ear or nose, Battle's sign). Focal neurological deficit For children who have sustained a head injury and have more than 1 of the following risk factors (and none of those in recommendation 1.4.9), perform a CT head scan within 1 hour of the risk factors being identified:

13 Page 13 of 23 Measure Importance Loss of consciousness lasting more than 5 minutes (witnessed). Abnormal drowsiness. Three or more discrete episodes of vomiting. Dangerous mechanism of injury (high-speed road traffic accident either as pedestrian, cyclist or vehicle occupant, fall from a height of greater than 3 metres, high-speed injury from a projectile or other object). Amnesia (antegrade or retrograde) lasting more than 5 minutes4. A provisional written radiology report should be made available within 1 hour of the scan being performed. [new 2014] Relationship to Desired Outcome Opportunity for Improvement Exception Justification Though it is difficult to directly attribute the effects of smaller dosages of radiation, such as that received through computed tomography (CT), there is evidence to suggest that the low dose radiation emitted through the use of some CT scans is associated with a significant risk of cancer, particularly in children. xiii As over 1.3 million individuals are treated and released from the ED for mild traumatic brain injury annually xiv, it is critical that CT scans only be utilized when clinically appropriate. Through measurement of the share of CT scans that are performed inappropriately, a focus can be brought to quality improvement and increased application of clinical decision tools around this topic. About 2.5 million traumatic brain injuries occur each year, where 75% of these are considered mild. xv There is data to suggest that 70% of head injury patients receive a head CT xvi, and it is estimated that 10-35% of head CTs obtained in head injury patients do not follow recognized guidelines. xvii Some estimate that as many as 55, ,000 CT scans are possibly avoidable annually. xviii The ACEP Measure Work Group agreed to include appropriate medical reasons as an exception so that clinicians can exclude patients for whom CT imaging may be justified. Harmonization with Existing Measures Measure Designation Measure purpose Type of measure National Quality Strategy Priority-CMS Measure Domain (check all that apply) Staff have considered harmonization with NQF 0668 Appropriate Head CT Imaging in Adults with Mild Traumatic Brain Injury. This measure will update NQF #0668 for implementation. Quality improvement Accountability MOC Process Outcome Structure Clinical Process-Effectiveness Patient Safety Patient Experience Care Coordination Efficiency: Overuse

14 Page 14 of 23 Level of Measurement (check all that apply) Care setting (check all that apply) Data source (check all that apply) Efficiency: Cost Population & Community Health Individual clinicians Clinician groups Hospital Outpatient/ED Emergency Departments Urgent Care Harmonize with other care settings o Physician Office Based Measures o Hospital Level Measure Electronic health record (EHR) data Administrative Data/Claims (inpatient, outpatient or multiple-source claims) Paper medical record/chart abstracted Registry

15 Page 15 of 23 Measure #3: Coagulation Studies in Adult Patients Presenting with Chest Pain with No Coagulopathy or Bleeding For this measure lower score indicates higher quality Measure Description Percentage of emergency department visits for patients aged 18 years and older with an emergency department discharge diagnosis of chest pain during which coagulation studies were ordered by an emergency care provider Measure Components Numerator Statement Statement Exclusions Exceptions emergency department visits during which coagulation studies (PT, PTT, or INR tests) were ordered by an emergency care provider All emergency department visits for patients aged 18 years and older with an emergency department discharge diagnosis of chest pain Patients with any of the following clinical indications for ordering coagulation studies: End stage liver disease Coagulopathy Thrombocytopenia Currently taking or newly prescribed any of the following anticoagulant medications: apixaban, argatroban, bivalirudin, dabigatran, dalteparin, desirudin, enoxaparin, fondaparinux, heparin, lepirudin, low molecular weight heparin, rivaroxaban, tinzaparin, warfarin Pregnancy Pulmonary or gastrointestinal hemorrhage Atrial fibrillation None

16 Page 16 of 23 Supporting Guideline & Other Evidence Rationale for the Measure Coagulation studies are often ordered out of habit as part of a blood panel with little value added to the patient. Ensuring that clinicians are purposefully ordering these studies may lead to significant reduction in resource utilization without any decrease in value of healthcare provided to the patient. Measure Importance Relationship to desired outcome Opportunity for Improvement Analyses have suggested that, in addition to the financial cost of performing unnecessary coagulation testing, there are other undesirable outcomes of unnecessary coagulation testing. These outcomes include increased false-positive results in low prevalence populations, an increase in unnecessary follow-up procedures, and an increase in unnecessary hospital days. xix In the United States, it is estimated that $114 million are spent annually on coagulation testing for patients presenting with chest pain and without any other indications in the Emergency Department. xx Across laboratory testing overall, between 15% to 56% of tests are considered to have been ordered inappropriately xxi ; in a study of coagulation studies specifically, it was found that 81% of coagulation tests were ordered inappropriately. xxii

17 Page 17 of 23 Exception Justification There are no exceptions for this measure. Harmonization with Existing Measures Harmonization with existing measures was not applicable to this measure. Measure Designation Measure purpose (check all that apply) Type of measure National Quality Strategy Priority/CMS Measure Domain (check all that apply) Level of Measurement (check all that apply) Care setting (check all that apply) Data source (check all that apply) Quality improvement Accountability MOC Process Outcome Structure Clinical Process-Effectiveness Patient Safety Patient Experience Care Coordination Efficiency: Overuse Efficiency: Cost Population & Community Health Individual clinicians Clinician groups Hospital Outpatient/ED Emergency Departments Urgent Care Harmonize with other care settings o Physician Office Based Measures o Hospital Level Measure Electronic health record (EHR) data Administrative Data/Claims (inpatient, outpatient or multiple-source claims) Paper medical record/chart Abstracted Registry

18 Page 18 of 23 Measure #4: Appropriate Emergency Department Utilization of CT for Pulmonary Embolism For this measure higher score indicates higher quality Measure Description Percentage of emergency department visits during which patients aged 18 years and older had a CT pulmonary angiogram (CTPA) ordered by an emergency care provider, regardless of discharge disposition, with either moderate or high pre-test clinical probability for pulmonary embolism OR positive result or elevated D-dimer level Measure Components Numerator Statement Statement Exclusions Exceptions emergency department visits with either: 1. Moderate or high pre-test clinical probability for pulmonary embolism OR 2. Positive result or elevated D-dimer level All emergency department visits during which patients aged 18 years and older had a CT pulmonary angiogram (CTPA) ordered by an emergency care provider, regardless of discharge disposition Patients with any of the following: Pregnancy Medical reason for ordering a CTPA without moderate or high pre-test clinical probability for pulmonary embolism AND no positive result or elevated D-dimer level (eg, CT ordered for aortic dissection) Supporting Guideline & Other Evidence The following evidence statements are quoted verbatim from the referenced clinical guidelines: Suspected non-high risk PE: Plasma D-dimer measurement is recommended in emergency department patients to reduce the needfor unnecessary imaging and irradiation, preferably using a highly sensitive assay (Class I Level A recommendation) Suspect non-high risk PE and low-clinical probability: Normal D-dimer level using either a highly or moderately sensitive assay excludes PE (Class I Level A recommendation) Suspect non-high risk PE and intermediate-clinical probability: Normal D-dimer level using a highly sensitive assay excludes PE, (Class I Level A recommendation) Suspect non-high risk PE and intermediate-clinical probability: Further testing should be considered if D-dimer level is normal when using a less sensitive assay (Class IIa Level B recommendation) xxiii

19 Page 19 of 23 The following evidence statements are quoted verbatim from the ACEP 2011 Clinical Policy: What is the role of the CT pulmonary angiogram of the chest as the sole diagnostic test in the exclusion of PE? Patient Management Recommendations Level A recommendations. None specified. Level B recommendations. For patients with a low or PE unlikely (Wells score <=4) pretest probability for PE who require additional diagnostic testing (eg, positive D- dimer result, or highly sensitive D-dimer test not available), a negative, multidetector CT pulmonary angiogram alone can be used to exclude PE. Level C recommendations. (1) For patients with an intermediate pretest probability for PE and a negative CT pulmonary angiogram result in whom a clinical concern for PE still exists and CT venogram has not already been performed, consider additional diagnostic testing (eg, D-dimer,* lower extremity imaging, VQ scanning, traditional pulmonary arteriography) prior to exclusion of VTE disease. (2) For patients with a high pretest probability for PE and a negative CT angiogram result, and CT venogram has not already been performed, perform additional diagnostic testing (eg, D-dimer,* lower extremity imaging, VQ scanning, traditional pulmonary arteriography) prior to exclusion of VTE disease. *A negative, highly sensitive, quantitative D-dimer result in combination with a negative multidetector CT pulmonary angiogram result theoretically provides a posttest probability of VTE less than 1% Wells Canadian Score for Assessment of pretest probability for PE Rationale for the Measure The goal of this measure is to reduce the inappropriate ordering of CTPA for pulmonary embolism based on pre-test probability estimation. This measure does not require utilization of a structured clinical prediction rule such as the Wells Score or Geneva Score, however the measure aims to improve efficiency by guiding clinical practice towards use of initial d-dimer testing rather than immediate CTPA in low or intermediate probability patients as indicated. Measure Importance Relationship to desired outcome In addition to imaging efficiency, the overuse of CTPA in ED patients with suspected pulmonary embolism has tangible implications for patient safety. Ionizing radiation from CTPA can increase the lifetime risk of cancer, particularly in young women due to the added vulnerability of breast tissue xxiv. Also, the use of iodinated dye places patients at risk of contrast induced nephropathy, which a study by Mitchell and Kline estimated at approximately 8% of all patients undergoing CTPA in the ED xxv xxvi.

20 Page 20 of 23 Opportunity for Improvement Despite significant evidence supporting the use of structured clinical assessment in combination with d-dimer testing to develop an evaluation of patients with suspected PE, there remains poor application of these algorithms in the ED setting xxvii. There are numerous studies demonstrating poor application of clinical pre-test assessment to PE testing strategies including: Single-center study demonstrated suboptimal application of Wells criteria as 25% of patients with a normal or intermediate probability d-dimer assays subsequently had CTPA ordered to evaluate for PE, with only 2.7% (0.7% of cohort) subsequently having PE xxviii. A large (5,344 patient) single center cohort study demonstrated that of 2,285 patients with negative d-dimer testing, 166 (7%) underwent CTPA, demonstrating inappropriate use of radiography outside established clinical algorithms xxix. Use of an ED protocol that combined structured clinical assessment with d-dimer testing doubles the rate of testing for PE, without increased imaging xxx. Exception Justification Harmonization with Existing Measures Measure Designation Measure purpose (check all that apply) Type of measure National Quality Strategy Priority/CMS Measure Domain (check all that apply) Level of Measurement (check all that apply) Care setting (check all that apply) Data source The ACEP Measure Work Group agreed to include appropriate medical reasons as an exception so that clinicians can exclude patients for whom CTPA for pulmonary embolism may be justified. Quality improvement Accountability MOC (to be determined by ABEM) Process Outcome Structure Clinical Process-Effectiveness Patient Safety Patient Experience Care Coordination Efficiency: Overuse Efficiency: Cost Population & Community Health Individual clinicians Clinician groups Hospital Outpatient/ED Emergency Departments Urgent Care Harmonize with other care settings o Physician Office Based Measures o Hospital Level Measure Electronic health record (EHR) data

21 Page 21 of 23 (check all that apply) Administrative Data/Claims (inpatient, outpatient or multiple-source claims) Paper medical record/chart Abstracted Registry

22 Page 22 of 23 References i Jagoda AS, Bazarlan JJ, Bruns JJ, et al. Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting. Ann Emerg Med. 2008;52: ii Jagoda AS, Bazarlan JJ, Bruns JJ, et al. Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting. Ann Emerg Med. 2008;52: iii Smith-Bindman, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Archives of internal medicine (2009): iv Smith-Bindman, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Archives of internal medicine (2009): v Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64- slice computed tomography coronary angiography. JAMA. 2007;298(3): vi Budoff MJ, Achenbach S, Blumenthal RS, et al. AHA scientific statement: Assessment of coronary artery disease by cardiac computed tomography. A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006; 114: vii Melnick, ER, Szlezak, CM, Bentley, SK, et al. CT Overuse for Mild Traumatic Brain Injury. The Joint Commission Journal on Quality and Patient Safety. 2012; 38(11): viii Centers for Disease Control and Prevention. Injury Prevention and Control: Traumatic Brain Injury. March 21, ix Stiell IG, Clement CM, Grimshaw JM, et al. A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departments. CMAJ x Melnick, ER, Szlezak, CM, Bentley, SK, et al. CT overuse for mild traumatic brain injury. Jt Comm J Qual Patient Saf 38(11): xi Stiell IG, Clement CM, Grimshaw JM, et al. A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departments. CMAJ xii Head Injury: Triage, assessment, investigation and early management of head injury in infants, children and adults. National Institute for Health and Clinical Excellence. September xiii Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics (2003): xiv Melnick, ER, Szlezak, CM, Bentley, SK, et al. CT Overuse for Mild Traumatic Brain Injury. The Joint Commission Journal on Quality and Patient Safety. 2012; 38(11): xv Centers for Disease Control and Prevention. Injury Prevention and Control: Traumatic Brain Injury. March 21, xvi Stiell IG, Clement CM, Grimshaw JM, et al. A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departments. CMAJ xvii Melnick, ER, Szlezak, CM, Bentley, SK, et al. CT overuse for mild traumatic brain injury. Jt Comm J Qual Patient Saf 38(11): xviii Stiell IG, Clement CM, Grimshaw JM, et al. A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departments. CMAJ xix Pilsczek FH, Rifkin, WD, Walerstein S. Overuse of prothrombin and partial thromboplastin coagulation tests in medical inpatients. Heart and Lung. 2005; 34(6): xx Kochert E, Goldhahn L, Hughes I, Gee K, Stahlman B. Cost-effectiveness of routine coagulation testing in the evaluation of chest pain in the ED. American Journal of Emergency Medicine (2012) 30, xxi Pilsczek FH, Rifkin, WD, Walerstein S. Overuse of prothrombin and partial thromboplastin coagulation tests in medical inpatients. Heart and Lung. 2005; 34(6): xxii Kochert E, Goldhahn L, Hughes I, Gee K, Stahlman B. Cost-effectiveness of routine coagulation testing in the evaluation of chest pain in the ED. American Journal of Emergency Medicine (2012) 30, xxiii Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J Sep;29(18): xxiv Brenner DJ, Hall EJ. Computed tomography an increasing source of radiation exposure. N Engl J Med. 2007;357:

23 Page 23 of 23 xxv Mitchell AM, Kline JA. Contrast nephropathy following computed tomography angiography of the chest for pulmonary embolism in the emergency department. J Thromb Haemost. 2007;5: xxvi Kline JA, Mitchell AM, Runyon MS, et al. Electronic medical record review as a surrogate to telephone followup to establish outcome for diagnostic research studies in the emergency department. Acad Emerg Med. 2005;12: xxvii Runyon MS, Richman PB, Kline JA. Emergency medicine practitioner knowledge and use of decision rules for the evaluation of patients with suspected pulmonary embolism: variations by practice setting and training level. Acad Emerg Med. 2007;14: xxviii Costantino MM, Randhall G, Gosselin M, et al. CT Angiography in the Evaluation of Acute Pulmonary Embolus. AJR 2008; 191: xxix Corwin MT, Donohoo JH, Patridge R, et al. Do Emergency Physicians Use Serum d-dimer Effectively to Determine the Need for CT When Evaluating Patients for Pulmonary Embolism? Review of 5,344 Consecutive Patients. AJR 2009; 192: xxx Kline JA, Webb WB, Jones AE, et al. Impact of a rapid rule-out protocol for pulmonary embolism on the rate of screening, missed cases, and pulmonary vascular imaging in an urban US emergency department. Ann Emerg Med. 2004;44:

Test Request Tip Sheet

Test Request Tip Sheet With/Without Contrast CT, MRI Studies should NOT be ordered simultaneously as dual studies (i.e., with and without contrast). Radiation exposure is doubled and both views are rarely necessary. The study

More information

NQF #IEP-005-10 Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism

NQF #IEP-005-10 Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism NQF #IEP-005-10 Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism Measure Description Rationale: The use of CT to evaluate patients with suspected pulmonary embolism (PE) has increased

More information

High Risk Emergency Medicine

High Risk Emergency Medicine High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose

More information

Guidelines and Protocols

Guidelines and Protocols TITLE: HEAD TRAUMA PURPOSE: To provide guidelines for rapid, accurate assessment of the head and intracranial structures for traumatic injury and to plan and implement appropriate interventions for identified

More information

Head Injury. Dr Sally McCarthy Medical Director ECI

Head Injury. Dr Sally McCarthy Medical Director ECI Head Injury Dr Sally McCarthy Medical Director ECI Head injury in the emergency department A common presentation 80% Mild Head Injury = GCS 14 15 10% Moderate Head Injury = GCS 9 13 10% Severe Head Injury

More information

SIGN. Early management of patients with a head injury. May 2009. A national clinical guideline. Scottish Intercollegiate Guidelines Network

SIGN. Early management of patients with a head injury. May 2009. A national clinical guideline. Scottish Intercollegiate Guidelines Network SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines - click here to complete our survey 110 Early management of patients with a

More information

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:

The Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures: Guidelines The following is a list of proposed medical specialty guidelines that have been found for the 11 targeted procedures to be included in the Medicare Imaging Demonstration. The list includes only

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,

More information

Medication Guidelines for LP/Myelograms Medication Recommendation Comments Plavix, Ticlid, other antiplatelet meds

Medication Guidelines for LP/Myelograms Medication Recommendation Comments Plavix, Ticlid, other antiplatelet meds Critical Laboratory Values for Lumbar Puncture/Myelography Lab Test PLT INR PTT Lab Value >25,000

More information

Service Specification Template Department of Health, updated June 2015

Service Specification Template Department of Health, updated June 2015 Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st

More information

Head injury. Triage, assessment, investigation and early management of head injury in infants, children and adults

Head injury. Triage, assessment, investigation and early management of head injury in infants, children and adults Issue date: September 2007 Head injury Triage, assessment, investigation and early management of head injury in infants, children and adults This is is a partial update of of NICE clinical guideline 4

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Jeff Yearley, BA Manager of Clinical Data Management Data Coordinating Center University of Utah. Slide 1/39

Jeff Yearley, BA Manager of Clinical Data Management Data Coordinating Center University of Utah. Slide 1/39 Design and Implementation of a Multi-Site Automated Data Acquisition Process from the Electronic Health Record (EHR) to an Electronic Data Capture System (EDC) Jeff Yearley, BA Manager of Clinical Data

More information

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2 Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can

More information

Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting

Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting TRAUMA/CLINICAL POLICY : Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting From the American College of Emergency Physicians (ACEP)/Centers for Disease Control and

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults

PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults PROTOCOL NUMBER: 7 PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults THIS PROTOCOL APPLIES TO: UW Health Clinics: all adult outpatients with an active order for warfarin TARGET

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

What You Should Know About Cerebral Aneurysms

What You Should Know About Cerebral Aneurysms What You Should Know About Cerebral Aneurysms From the Cerebrovascular Imaging and Interventions Committee of the American Heart Association Cardiovascular Radiology Council Randall T. Higashida, M.D.,

More information

Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas

Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas Billing and Coding in Neurology and Headache Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas CPT Codes vs. ICD Codes Category

More information

Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients

Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients What is a Deep Vein Thrombosis (DVT)? A DVT is a blood clot which forms in a deep vein, usually in

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

AACN Statement of Support for Clinical Nurse Specialists

AACN Statement of Support for Clinical Nurse Specialists AACN Statement of Support for Clinical Nurse Specialists The American Association of Colleges of Nursing (AACN) is committed to advancing professional nursing roles and highlighting the connection between

More information

Radiology Physician Performance Measurement Set

Radiology Physician Performance Measurement Set American College of Radiology/ Physician Consortium for Performance Improvement / National Committee for Quality Assurance Radiology Physician Performance Measurement Set October 2007 Radiology Work Group

More information

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has

More information

Measure #145: Radiology: Exposure Time Reported for Procedures Using Fluoroscopy National Quality Strategy Domain: Patient Safety

Measure #145: Radiology: Exposure Time Reported for Procedures Using Fluoroscopy National Quality Strategy Domain: Patient Safety Measure #145: Radiology: Exposure Time Reported for Procedures Using Fluoroscopy National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:

More information

Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care

Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:

More information

TITLE 836 INDIANA EMERGENCY MEDICAL SERVICES COMMISSION. ARTICLE 1.5 Trauma Field Triage and Transport Destination Requirements

TITLE 836 INDIANA EMERGENCY MEDICAL SERVICES COMMISSION. ARTICLE 1.5 Trauma Field Triage and Transport Destination Requirements TITLE 836 INDIANA EMERGENCY MEDICAL SERVICES COMMISSION ARTICLE 1.5 Trauma Field Triage and Transport Destination Requirements 836 IAC 1.5-1 Purpose Affected: [IC 10-14-3-12; IC 16-18; IC 16-21-2; IC 16-31-2-9;

More information

PREVENTIVE MEDICINE AND SCREENING POLICY

PREVENTIVE MEDICINE AND SCREENING POLICY REIMBURSEMENT POLICY PREVENTIVE MEDICINE AND SCREENING POLICY Policy Number: ADMINISTRATIVE 238.13 T0 Effective Date: January 1, 2016 Table of Contents APPLICABLE LINES OF BUSINESS/PRODUCTS... APPLICATION...

More information

HEAD INJURIES V S U H E A L T H C E N T E R V A L D O S T A S T A T E U N I V E R S I T Y F A L L 2 0 1 2

HEAD INJURIES V S U H E A L T H C E N T E R V A L D O S T A S T A T E U N I V E R S I T Y F A L L 2 0 1 2 HEAD INJURIES V S U H E A L T H C E N T E R V A L D O S T A S T A T E U N I V E R S I T Y F A L L 2 0 1 2 LET S TALK ABOUT BRAIN INJURIES! Traumatic head injury affects more than 1.7 million people in

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Diagnostic Imaging Management

Diagnostic Imaging Management Diagnostic Imaging Management Frequently Asked Questions (FAQ) from Providers Updated August 1, 2013 Program Overview Q1. What is AIM Specialty Health SM (AIM)? A1. AIM Specialty Health SM (AIM) is a leading

More information

New Anticoagulants: What to Use What to Avoid

New Anticoagulants: What to Use What to Avoid New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant

More information

2011 Radiology Diagnosis Coding Update Questions and Answers

2011 Radiology Diagnosis Coding Update Questions and Answers 2011 Radiology Diagnosis Coding Update Questions and Answers How can we subscribe to the Coding Clinic for ICD-9 guidelines and updates? The American Hospital Association publishes this quarterly newsletter.

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

Center for Medicare and Medicaid Innovation

Center for Medicare and Medicaid Innovation Center for Medicare and Medicaid Innovation Summary: Establishes within the Centers for Medicare and Medicaid Services (CMS) a Center for Medicare & Medicaid Innovation (CMI). The purpose of the Center

More information

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...

More information

TRAUMA PATIENT TRANSPORT

TRAUMA PATIENT TRANSPORT TRAUMA PATIENT TRANSPORT I. Region XI EMS uses a pre-hospital scoring system (see Attachment 1, Trauma Field Triage Criteria) to assist with the identification of injured adult and pediatric patients and

More information

Gruppo di lavoro: Malattie Tromboemboliche

Gruppo di lavoro: Malattie Tromboemboliche Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant

More information

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment

More information

APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis)

APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis) APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis) APPLICANT S INSTRUCTIONS: 1. Answer all questions. If the answer requires detail, please attach a separate

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #226 (NQF 0028): Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

Pulmonary Embolism Treatment Update

Pulmonary Embolism Treatment Update UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose

More information

Diagnosis and Treatment of VTE in the ER

Diagnosis and Treatment of VTE in the ER UHN ER Conference Nov 3, 2015 Diagnosis and Treatment of VTE in the ER Bill Geerts Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Canadian

More information

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:

More information

2015 Data Validation Strategy

2015 Data Validation Strategy 2015 Data Validation Strategy This data validation strategy details how the American College of Emergency Physicians (ACEP), a medical specialty society representing more than 33,000 emergency physicians,

More information

APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis)

APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis) APPLICATION FOR CHIROPRACTORS PROFESSIONAL LIABILITY INSURANCE (Claims Made and Reported Basis) APPLICANT'S INSRUCTIONS: 1. Answer all questions. If the answer requires detail, please attach a separate

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care

Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care Measure #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of patients

More information

Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care

Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

More information

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT

More information

Level III Stroke Center Data Collection Requirements

Level III Stroke Center Data Collection Requirements Who? Level III Stroke Center Data Collection Requirements All LERN Level III Stroke Centers. LERN Level I and II Stroke Centers have reporting requirements to The Joint Commission or other Board approved

More information

To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism.

To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism. PULMONARY EMBOLISM: DIAGNOSIS AND MANAGEMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary

More information

SOURCES AND EFFECTS OF IONIZING RADIATION

SOURCES AND EFFECTS OF IONIZING RADIATION SOURCES AND EFFECTS OF IONIZING RADIATION United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2008 Report to the General Assembly with Scientific Annexes VOLUME I UNITED NATIONS

More information

SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]

SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D] I. Definitions: Detoxification is the process of interrupting the momentum of compulsive drug and/or alcohol use in an individual

More information

Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective

Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk

More information

Anticoagulation Therapy Update

Anticoagulation Therapy Update Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2

More information

A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT

A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to

More information

Perceived Workplace Discrimination as a Mediator of the Relationship between Work Environment and Employee Outcomes: Does Minority Status Matter?

Perceived Workplace Discrimination as a Mediator of the Relationship between Work Environment and Employee Outcomes: Does Minority Status Matter? University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School 7-12-2010 Perceived Workplace Discrimination as a Mediator of the Relationship between Work Environment and

More information

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight

More information

Overview of the TJC/CMS VTE Core Measures

Overview of the TJC/CMS VTE Core Measures Overview of the TJC/CMS VTE Core Measures CMS Specification Manual 4.2 January 1, 2013 June 30, 2013 Victoria Agramonte, RN, MSN Project Manager, IPRO VTE Regional Learning Sessions NYS Partnership for

More information

Management of mild and moderate head injuries in adults

Management of mild and moderate head injuries in adults Romanian Neurosurgery (2010) XVII 4: 421 431 421 Management of mild and moderate head injuries in adults Dana Turliuc, A. Cucu Universitatea de Medicină şi Farmacie Gr.T. Popa Iasi Shock is a respite on

More information

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

What You Need to KnowWhen Taking Anticoagulation Medicine

What You Need to KnowWhen Taking Anticoagulation Medicine What You Need to KnowWhen Taking Anticoagulation Medicine What are anticoagulant medicines? Anticoagulant medicines are a group of medicines that inhibit blood clotting, helping to prevent blood clots.

More information

The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia

The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia By Scott Knight, Director, SLR Diagnostics & Assessments, a division of Sibley & Associates Inc., and Konstantine

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

U.S. Bureau of Labor Statistics. Radiology Tech

U.S. Bureau of Labor Statistics. Radiology Tech From the: U.S. Bureau of Labor Statistics Radiology Tech What They Do Radiologic technologists (RTs) perform diagnostic imaging examinations, such as x rays, on patients. Duties RTs typically do the following:

More information

Confirmed Deep Vein Thrombosis (DVT)

Confirmed Deep Vein Thrombosis (DVT) Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Workflow Administration of Windchill 10.2

Workflow Administration of Windchill 10.2 Workflow Administration of Windchill 10.2 Overview Course Code Course Length TRN-4339-T 2 Days In this course, you will learn about Windchill workflow features and how to design, configure, and test workflow

More information

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs? Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet

More information

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012. 1 AR SAVES INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012. 2 Objectives To provide an introduction and overall description of AR SAVES as a Telestroke Network in the

More information

MEDICAL POLICY No. 91104-R7 DETOXIFICATION I. POLICY/CRITERIA

MEDICAL POLICY No. 91104-R7 DETOXIFICATION I. POLICY/CRITERIA DETOXIFICATION MEDICAL POLICY Effective Date: January 7, 2013 Review Dates: 1/93, 2/97, 4/99, 2/01, 12/01, 2/02, 2/03, 1/04, 1/05, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11, 12/12, 12/13, 11/14 Date

More information

Title: NON-ACCIDENTAL TRAUMA SCREENING AND MANAGEMENT GUIDELINE

Title: NON-ACCIDENTAL TRAUMA SCREENING AND MANAGEMENT GUIDELINE Patient Care Clinical/Medication Guideline Title: NON-ACCIDENTAL TRAUMA SCREENING AND MANAGEMENT GUIDELINE Scope/Patient Population: Pediatric patients evaluated in MHS Emergency Departments, Pediatric

More information

What Does it Mean When Patients Choose Wisely? David Ansley Senior Analyst, Health Product Development Consumer Reports

What Does it Mean When Patients Choose Wisely? David Ansley Senior Analyst, Health Product Development Consumer Reports What Does it Mean When Patients Choose Wisely? David Ansley Senior Analyst, Health Product Development Consumer Reports People are realizing that more medicine is not necessarily better. And that we re

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

Introduction. Background to this event. Raising awareness 09/11/2015

Introduction. Background to this event. Raising awareness 09/11/2015 Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness

More information

Traumatic brain injury (TBI)

Traumatic brain injury (TBI) Traumatic brain injury (TBI) A topic in the Alzheimer s Association series on understanding dementia. About dementia Dementia is a condition in which a person has significant difficulty with daily functioning

More information

6.0 Management of Head Injuries for Maxillofacial SHOs

6.0 Management of Head Injuries for Maxillofacial SHOs 6.0 Management of Head Injuries for Maxillofacial SHOs As a Maxillofacial SHO you are not required to manage established head injury, however an awareness of the process is essential when dealing with

More information

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis

More information

Toronto Acquired Brain Injury Network. Response to the Catastrophic Impairment Report I Consultation

Toronto Acquired Brain Injury Network. Response to the Catastrophic Impairment Report I Consultation Toronto Acquired Brain Injury Network Response to the Catastrophic Impairment Report I Consultation May 13, 2011 to Recommendations for Changes to the Definition of Catastrophic Impairment: Final Report

More information

Redefining the NSTEACS pathway in London

Redefining the NSTEACS pathway in London Redefining the NSTEACS pathway in London Sotiris Antoniou Consultant Pharmacist, Cardiovascular Medicine, Barts and The London NHS Trust and Project Lead, North East London Cardiovascular and Stroke Network

More information

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding

More information

Preventing Blood Clots in Adult Patients. Information For Patients

Preventing Blood Clots in Adult Patients. Information For Patients Preventing Blood Clots in Adult Patients Information For Patients 1 This leaflet will give you information on how to reduce the risk of developing blood clots during and after your stay in hospital. If

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Connecticut Health Care Costs

Connecticut Health Care Costs How much does Connecticut spend on health care? Connecticut Health Care Costs In 2009 Connecticut spent $30.4 billion dollars on health care. That is $8,653.57 for every state resident. And those costs

More information